Fludarabine and once-daily intravenous busulfan for allogeneic bone marrow transplantation for Chediak-Higashi syndrome.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of pediatric hematology/oncology

• Publication date

  2003-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00043426-200310000-00019PMID 14528111
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II study of a moderate-intensity preparative regimen with allogeneic peripheral blood stem cell transplantation for hematologic diseases: the Texas Transplant Consortium experience.

  2002cited by this paper
• Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation.

  2002cited by this paper
• Endocrine late effects after bone marrow transplant.

  2002cited by this paper
• Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study.

  2002cited by this paper
• Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.

  2002cited by this paper
• Non-endocrine late complications of bone marrow transplantation in childhood: part II.

  2002cited by this paper
• Cellular and Clinical Pharmacology of Fludarabine

  2002cited by this paper
• Successful HLA-identical bone marrow transplantation in a patient with PNP deficiency using busulfan and fludarabine for conditioning

  2001cited by this paper
• Chédiak–Higashi syndrome: hematopoietic chimerism corrects genetic defect

  2001influential reference
• Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy.

  2000cited by this paper
• Fludarabine-based preparative protocol for unrelated donor cord blood transplantation in children: successful engraftment with minimal toxicity

  1999cited by this paper
• Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome.

  1999cited by this paper
• Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.

  1998cited by this paper
• Treatment of Chediak-Higashi syndrome by allogenic bone marrow transplantation: report of 10 cases.

  1995cited by this paper
• Allogeneic bone marrow transplantation in Chédiak-Higashi syndrome.

  1995influential reference
• Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia.

  1994cited by this paper
• The "lazy" NK cells of Chediak-Higashi syndrome.

  1983influential reference
• Reversal of natural killer defect in a patient with Chédiak-Higashi syndrome after bone-marrow transplantation.

  1982cited by this paper
• Correction of leukocyte function in Chediak-Higashi syndrome by ascorbate.

  1976influential reference

• IGF-1, Inflammation and Retinal Degeneration: A Close Network

  2018cites this paper
• Hematopoietic Cell Transplantation for Macrophage, Granulocyte and Osteoclast Disorders

  2016cites this paper
• Optimizing drug therapy in pediatric SCT: Focus on pharmacokinetics

  2015cites this paper
• Accelerated Phase at Initial Presentation in Chédiak-Higashi Syndrome: Is It Really Uncommon ?

  2014cites this paper
• Novel approach to characterize developmental changes in pharmacokinetics across the human lifespan : application to the prediction of clearance in children

  2013cites this paper
• Body weight-dependent pharmacokinetics of busulfan in pediatric hematopoietic stem cell transplantation patients: towards individualized dosing

  2013cites this paper
• This material is the copyright of the original publisher. Unauthorised copying and distribution is prohibited. Body Weight-Dependent Pharmacokinetics of Busulfan in Paediatric Haematopoietic Stem Cell Transplantation Patients

  2012cites this paper
• Body Weight-Dependent Pharmacokinetics of Busulfan in Paediatric Haematopoietic Stem Cell Transplantation Patients

  2012cites this paper
• Chediak-Higashi syndrome: report of a case with uncommon presentation and review literature.

  2006cites this paper
• Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring

  2005cites this paper
• B harmacokinetics and Individualized Dose djustment of Intravenous Busulfan in Children with dvanced Hematologic Malignancies Undergoing llogeneic Stem Cell Transplantation

  2004cites this paper
• Update on childhood neutropenia: molecular and clinical advances.

  2004cites this paper
• Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.

  2004cites this paper